scholarly article | Q13442814 |
P356 | DOI | 10.1056/NEJM199807303390503 |
P698 | PubMed publication ID | 9696640 |
P433 | issue | 5 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | aciclovir | Q147101 |
prevention | Q1717246 | ||
eye disease | Q3041498 | ||
P304 | page(s) | 300-306 | |
P577 | publication date | 1998-07-01 | |
P1433 | published in | The New England Journal of Medicine | Q582728 |
P1476 | title | Acyclovir for the prevention of recurrent herpes simplex virus eye disease. Herpetic Eye Disease Study Group | |
P478 | volume | 339 |
Q24202587 | Q24202587 |
Q35769258 | A Herpes Simplex Virus Type 1 Human Asymptomatic CD8+ T-Cell Epitopes-Based Vaccine Protects Against Ocular Herpes in a "Humanized" HLA Transgenic Rabbit Model |
Q39638812 | A cationic TAT peptide inhibits Herpes simplex virus type 1 infection of human corneal epithelial cells |
Q35220431 | A herpes simplex virus type 1 mutant disrupted for microRNA H2 with increased neurovirulence and rate of reactivation |
Q40867805 | A plasmid construct encoding murine interferon beta antagonizes the replication of herpes simplex virus type I in vitro and in vivo |
Q30777273 | Accounting for misclassified outcomes in binary regression models using multiple imputation with internal validation data |
Q34034789 | An important role for syndecan-1 in herpes simplex virus type-1 induced cell-to-cell fusion and virus spread |
Q73904737 | Anterior uveitis with sectoral iris atrophy in the absence of keratitis: a distinct clinical entity among herpetic eye diseases |
Q43775824 | Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model |
Q37414696 | Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus |
Q30847945 | Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B |
Q40216595 | CXCL10/CXCR3-Dependent Mobilization of Herpes Simplex Virus-Specific CD8+ TEM and CD8+ TRM Cells within Infected Tissues Allows Efficient Protection against Recurrent Herpesvirus Infection and Disease |
Q57488314 | Clinical Features of Herpes Simplex Keratitis in a Korean Tertiary Referral Center: Efficacy of Oral Antiviral and Ascorbic Acid on Recurrence |
Q36816198 | Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis |
Q34623643 | Clinical features and prognosis of herpetic anterior uveitis: a retrospective study of 111 cases |
Q37443032 | Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient |
Q89866345 | Concomitant herpetic keratitis and acute retinal necrosis: clinical features and outcomes |
Q36359783 | Confocal Microscopic Analysis of a Rabbit Eye Model of High-Incidence Recurrent Herpes Stromal Keratitis. |
Q44165410 | Corneal herpes: what's new? |
Q37857665 | Corneal latency and transmission of herpes simplex virus-1. |
Q80883371 | Current clinical practice of consultant ophthalmologists in treating herpetic eye disease in the United Kingdom |
Q36555158 | Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2. |
Q42199077 | Cytomegalovirus anterior uveitis: long-term follow-up of immunocompetent patients. |
Q47115686 | Decision-making and management of uveitic cataract |
Q36199997 | Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation |
Q36460600 | Diversity of microbial species implicated in keratitis: a review |
Q33982508 | Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits |
Q44605033 | Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial |
Q41468795 | Effects of antiviral medications on herpetic epithelial keratitis in mice |
Q46138251 | Efficacy and safety of latanoprost in eyes with uveitic glaucoma. |
Q36626903 | Efficacy of a helicase-primase inhibitor in animal models of ocular herpes simplex virus type 1 infection |
Q36895307 | Evidence-based treatment of herpes simplex virus keratitis: a systematic review. |
Q36025675 | Future of an "Asymptomatic" T-cell Epitope-Based Therapeutic Herpes Simplex Vaccine |
Q27026675 | Ganciclovir ophthalmic gel 0.15% for the treatment of acute herpetic keratitis: background, effectiveness, tolerability, safety, and future applications |
Q33654708 | Gene expression profiling of transporters in the solute carrier and ATP-binding cassette superfamilies in human eye substructures |
Q34366070 | HSV-1 infection of human corneal epithelial cells: receptor-mediated entry and trends of re-infection. |
Q95840901 | Herpes Simplex Virus: The Hostile Guest That Takes Over Your Home |
Q44165415 | Herpes and retinal lesions: what's new? |
Q34297293 | Herpes keratitis |
Q26853504 | Herpes simplex epithelial and stromal keratitis: an epidemiologic update |
Q37603658 | Herpes simplex keratitis: challenges in diagnosis and clinical management. |
Q37949631 | Herpes simplex virus infects most cell types in vitro: clues to its success |
Q37160338 | High-level expression of glycoprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection |
Q57753552 | Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107 CD8 T Cells That Infiltrate the Corneas and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protect ag |
Q35868029 | Immunodominant "asymptomatic" herpes simplex virus 1 and 2 protein antigens identified by probing whole-ORFome microarrays with serum antibodies from seropositive asymptomatic versus symptomatic individuals |
Q35012576 | Incidence, recurrence, and outcomes of herpes simplex virus eye disease in Olmsted County, Minnesota, 1976-2007: the effect of oral antiviral prophylaxis |
Q36366295 | Increased neurovirulence and reactivation of the herpes simplex virus type 1 latency-associated transcript (LAT)-negative mutant dLAT2903 with a disrupted LAT miR-H2 |
Q44435875 | Influence of preparation conditions on acyclovir-loaded poly-d,l-lactic acid nanospheres and effect of PEG coating on ocular drug bioavailability |
Q31983928 | LASIK complications: etiology, management, and prevention |
Q37699098 | Large Amounts of Reactivated Virus in Tears Precedes Recurrent Herpes Stromal Keratitis in Stressed Rabbits Latently Infected with Herpes Simplex Virus |
Q43187227 | Medical management approach to infectious keratitis |
Q34757252 | Meganuclease-mediated Inhibition of HSV1 Infection in Cultured Cells |
Q90163562 | MicroRNAs in Ocular Infection |
Q36520832 | Mucosal herpes immunity and immunopathology to ocular and genital herpes simplex virus infections |
Q44922924 | Necrotic herpetic retinitis |
Q83839404 | Ocular herpes simplex |
Q39024630 | Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. |
Q94569106 | Overview of antiviral medications used in ophthalmology |
Q35590400 | Pathogenesis and management of herpes simplex virus keratitis |
Q57476625 | Pathogenesis of herpes simplex keratitis: The host cell response and ocular surface sequelae to infection and inflammation |
Q37058919 | Practice patterns and opinions in the management of recurrent or chronic herpes zoster ophthalmicus |
Q41882382 | Practice patterns for herpes simplex keratitis: A survey of ophthalmologists in Gulf Coast countries |
Q34717035 | Prophylaxis of herpesvirus infections in immunocompetent and immunocompromised older patients |
Q47547941 | Reactivation of herpes simplex viral keratitis following the botulinum toxin injection |
Q52019903 | Recall bias in a prospective cohort study of acute time-varying exposures: example from the herpetic eye disease study. |
Q43881072 | Specific antibody production in herpes keratitis: intraocular inflammation and corneal neovascularisation as predicting factors |
Q37767618 | Suppression of herpes simplex virus 1 reactivation in a mouse eye model by cyclooxygenase inhibitor, heat shock protein inhibitor, and adenosine monophosphate |
Q33826410 | Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. |
Q44922927 | The latest in herpes simplex keratitis therapy |
Q35589785 | The outcome of corneal grafting in patients with stromal keratitis of herpetic and non-herpetic origin |
Q33722270 | The placebo effect |
Q35113991 | The red eye in childhood |
Q35745358 | Therapeutic immunization with a mixture of herpes simplex virus 1 glycoprotein D-derived “asymptomatic” human CD8+ T-cell epitopes decreases spontaneous ocular shedding in latently infected HLA transgenic rabbits: association with low frequency of l |
Q39840108 | Topical ganciclovir in the treatment of acute herpetic keratitis |
Q80265715 | Topical treatment with nerve growth factor in an animal model of herpetic keratitis |
Q21296712 | Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown |
Q33805830 | Treatment of viral diseases of the cornea and external eye. |
Q98726066 | Update on Herpes simplex keratitis management |
Q41931288 | Update on the Management of Infectious Keratitis |
Q41140880 | Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. |
Q30979930 | Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy |
Q83745516 | ["Herpetic keratitis". Various expressions require different therapeutic approaches] |
Q54400543 | [Secondary glaucoma in uveitis]. |
Q80163758 | [Viral uveitis] |
Search more.